Hepatitis C Virus Infection and the New Therapeutical Approach

Overview

Journal Curr Health Sci J

Specialty General Medicine

Date 2022 Jan 10

PMID 35003766

Authors

Claudia Monica Danilescu

Mihail Cristian Pirlog

Ion Rogoveanu

Affiliations

Soon will be listed here.

Abstract

Hepatitis C virus represents one of the most important public health problems nowadays. Several epidemiological studies have shown a continuous increasing rate of prevalence and incidence with severe consequences in terms of mortality. During the last decades, the treatment of the liver infection has evolved, and now there are available new therapies with better side-effect' profiles and bigger efficiency. The needs for more therapeutically efficacy also stand behind the numerous comorbidities associated to the liver disease, and also for assuring better quality of life for patients and their families.

References

Davis G, Esteban-Mur R, Rustgi V, Hoefs J, Gordon S, Trepo C . Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med. 1998; 339(21):1493-9. DOI: 10.1056/NEJM199811193392102. View

Haroon E, Raison C, Miller A . Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology. 2011; 37(1):137-62. PMC: 3238082. DOI: 10.1038/npp.2011.205. View

Hagan H, Campbell J, Thiede H, Strathdee S, Ouellet L, Kapadia F . Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Public Health Rep. 2007; 121(6):710-9. PMC: 1781913. DOI: 10.1177/003335490612100611. View

Younossi Z, Stepanova M, Reddy R, Manns M, Bourliere M, Gordon S . Viral eradication is required for sustained improvement of patient-reported outcomes in patients with hepatitis C. Liver Int. 2018; 39(1):54-59. DOI: 10.1111/liv.13900. View

Kiser J, Burton Jr J, Everson G . Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013; 10(10):596-606. PMC: 4634866. DOI: 10.1038/nrgastro.2013.106. View

Hsu Y, Ho H, Huang Y, Wang H, Wu M, Lin J . Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2014; 64(3):495-503. DOI: 10.1136/gutjnl-2014-308163. View

Goni Esarte S, Juanbeltz R, Martinez-Baz I, Castilla J, San Miguel R, Herrero J . Long-term changes on health-related quality of life in patients with chronic hepatitis C after viral clearance with direct-acting antiviral agents. Rev Esp Enferm Dig. 2019; 111(6):445-452. DOI: 10.17235/reed.2019.6063/2018. View

Janjua N, Wong S, Abdia Y, Jeong D, Buller-Taylor T, Adu P . Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study. J Hepatol. 2021; 75(5):1049-1057. DOI: 10.1016/j.jhep.2021.05.028. View

Soriano V, Labarga P, Barreiro P, Fernandez-Montero J, de Mendoza C, Esposito I . Drug interactions with new hepatitis C oral drugs. Expert Opin Drug Metab Toxicol. 2015; 11(3):333-41. DOI: 10.1517/17425255.2015.998997. View

10.

San Miguel R, del Villar V, Perez C, de Frutos M, Mar J, Coma M . Role of health-related quality of life measurements in the design of drug clinical trials. Farm Hosp. 2010; 34(1):16-22. DOI: 10.1016/j.farma.2009.07.002. View

11.

Mavilia M, Wu G . HBV-HCV Coinfection: Viral Interactions, Management, and Viral Reactivation. J Clin Transl Hepatol. 2018; 6(3):296-305. PMC: 6160312. DOI: 10.14218/JCTH.2018.00016. View

12.

Argentini C, Genovese D, Dettori S, Rapicetta M . HCV genetic variability: from quasispecies evolution to genotype classification. Future Microbiol. 2009; 4(3):359-73. DOI: 10.2217/fmb.09.8. View

13.

Fabrizi F, Donato F, Messa P . Direct-acting antivirals for hepatitis C virus in patients on maintenance dialysis. Int J Artif Organs. 2017; 40(10):531-541. DOI: 10.5301/ijao.5000613. View

14.

Simmonds P . Genetic diversity and evolution of hepatitis C virus--15 years on. J Gen Virol. 2004; 85(Pt 11):3173-3188. DOI: 10.1099/vir.0.80401-0. View

15.

Forton D, Thomas H, Taylor-Robinson S . Central nervous system involvement in hepatitis C virus infection. Metab Brain Dis. 2004; 19(3-4):383-91. DOI: 10.1023/b:mebr.0000043983.42843.ac. View

16.

Backus L, Boothroyd D, Phillips B, Belperio P, Halloran J, Mole L . A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011; 9(6):509-516.e1. DOI: 10.1016/j.cgh.2011.03.004. View

17.

Forton D, Hamilton G, Allsop J, Grover V, Wesnes K, OSullivan C . Cerebral immune activation in chronic hepatitis C infection: a magnetic resonance spectroscopy study. J Hepatol. 2008; 49(3):316-22. DOI: 10.1016/j.jhep.2008.03.022. View

18.

Hoofnagle J . Course and outcome of hepatitis C. Hepatology. 2002; 36(5 Suppl 1):S21-9. DOI: 10.1053/jhep.2002.36227. View

19.

Cillo U, Amodio P, Ronco C, Soni S, Zanus G, Minazzato L . Hepatitis C virus adversely affects quality of life. Blood Purif. 2011; 32(2):144-9. DOI: 10.1159/000325222. View

20.

Davoodi L, Masoum B, Moosazadeh M, Jafarpour H, Haghshenas M, Mousavi T . Psychiatric side effects of pegylated interferon-α and ribavirin therapy in Iranian patients with chronic hepatitis C: A meta-analysis. Exp Ther Med. 2018; 16(2):971-978. PMC: 6090315. DOI: 10.3892/etm.2018.6255. View